Global BCG Vaccine Market Growth 2025-2031
Description
The global BCG Vaccine market size is predicted to grow from US$ 80.8 million in 2025 to US$ 97 million in 2031; it is expected to grow at a CAGR of 3.2% from 2025 to 2031.
BCG Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80%of neonates and infants in countries where it is part of the national childhood immunization programme.
Market Drivers for BCG Vaccine:
High Prevalence of Tuberculosis (TB): The increasing incidence of TB, especially in densely populated and low-income countries, drives the demand for BCG vaccines to prevent the disease, particularly among children and healthcare workers.
Rising Awareness and Immunization Programs: Many governments and health organizations promote vaccination to control TB outbreaks, providing funding and infrastructure to distribute BCG vaccines widely, particularly in high-risk regions.
Growing Healthcare Investments in Emerging Markets: Expanding healthcare infrastructure and government spending in emerging economies have increased the availability and accessibility of the BCG vaccine.
Development of New TB Strains: The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains has highlighted the need for effective preventative measures like the BCG vaccine.
Market Challenges for BCG Vaccine:
Limited Efficacy in Adults: The BCG vaccine’s effectiveness diminishes in adults, as it primarily prevents severe forms of TB in children rather than pulmonary TB, which is common in adults.
Side Effects and Safety Concerns: For individuals with weakened immune systems, the live BCG vaccine may pose health risks, which restricts its use among certain populations.
Supply Chain Constraints: Manufacturing challenges and periodic shortages impact the availability of BCG vaccines in some regions, particularly low-income countries.
Competition from New Vaccines and Treatments: Research on new TB vaccines and alternative treatments could reduce the reliance on BCG, especially if future solutions offer broader protection across age groups.
LP Information, Inc. (LPI) ' newest research report, the “BCG Vaccine Industry Forecast” looks at past sales and reviews total world BCG Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected BCG Vaccine sales for 2025 through 2031. With BCG Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world BCG Vaccine industry.
This Insight Report provides a comprehensive analysis of the global BCG Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on BCG Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global BCG Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for BCG Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global BCG Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of BCG Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Immune Vaccine
Therapy Vaccine
Segmentation by Application:
Self-Procurement
UNICEF
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC – Institute of Vaccines and Medical Biologicals
Queen Saovabha Mem. Inst
Microgen
Key Questions Addressed in this Report
What is the 10-year outlook for the global BCG Vaccine market?
What factors are driving BCG Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do BCG Vaccine market opportunities vary by end market size?
How does BCG Vaccine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
BCG Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and sometimes other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80%of neonates and infants in countries where it is part of the national childhood immunization programme.
Market Drivers for BCG Vaccine:
High Prevalence of Tuberculosis (TB): The increasing incidence of TB, especially in densely populated and low-income countries, drives the demand for BCG vaccines to prevent the disease, particularly among children and healthcare workers.
Rising Awareness and Immunization Programs: Many governments and health organizations promote vaccination to control TB outbreaks, providing funding and infrastructure to distribute BCG vaccines widely, particularly in high-risk regions.
Growing Healthcare Investments in Emerging Markets: Expanding healthcare infrastructure and government spending in emerging economies have increased the availability and accessibility of the BCG vaccine.
Development of New TB Strains: The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains has highlighted the need for effective preventative measures like the BCG vaccine.
Market Challenges for BCG Vaccine:
Limited Efficacy in Adults: The BCG vaccine’s effectiveness diminishes in adults, as it primarily prevents severe forms of TB in children rather than pulmonary TB, which is common in adults.
Side Effects and Safety Concerns: For individuals with weakened immune systems, the live BCG vaccine may pose health risks, which restricts its use among certain populations.
Supply Chain Constraints: Manufacturing challenges and periodic shortages impact the availability of BCG vaccines in some regions, particularly low-income countries.
Competition from New Vaccines and Treatments: Research on new TB vaccines and alternative treatments could reduce the reliance on BCG, especially if future solutions offer broader protection across age groups.
LP Information, Inc. (LPI) ' newest research report, the “BCG Vaccine Industry Forecast” looks at past sales and reviews total world BCG Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected BCG Vaccine sales for 2025 through 2031. With BCG Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world BCG Vaccine industry.
This Insight Report provides a comprehensive analysis of the global BCG Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on BCG Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global BCG Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for BCG Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global BCG Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of BCG Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Immune Vaccine
Therapy Vaccine
Segmentation by Application:
Self-Procurement
UNICEF
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC – Institute of Vaccines and Medical Biologicals
Queen Saovabha Mem. Inst
Microgen
Key Questions Addressed in this Report
What is the 10-year outlook for the global BCG Vaccine market?
What factors are driving BCG Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do BCG Vaccine market opportunities vary by end market size?
How does BCG Vaccine break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
119 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for BCG Vaccine by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for BCG Vaccine by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
